Amplifon, a global leader in the distribution of hearing aids, saw its stock rise by 3.2% to 10.77 euros yesterday, as analysts express optimism about the company's future performance. Despite facing challenges in 2025, CEO Enrico Vita's group is viewed as being in a temporary transitional phase, with market confidence remaining strong based on recent analysis by Equita.

Equita reaffirmed a 'buy' rating for Amplifon, setting a target price of 20 euros per share, suggesting a potential upside of almost 90% from current values. The brokerage notes that the stock is trading at discounts compared to the multiples paid during acquisitions of small independent chains in the European market. This price recovery comes after a significant sell-off following the results of the fourth quarter of 2025, indicating that the stock is currently undervalued and likely to rebound as market conditions improve.

Market analysts believe that once Amplifon navigates through its transitional challenges, it is poised to unlock significant upside potential. Investors may find this an opportune time to acquire shares, anticipating that the company's fundamentals will lead to a bullish momentum in the near future. If Amplifon's performance aligns with analyst expectations, it could attract further investments and bolster its market position, making it a noteworthy player in the health technology sector.